kneat.com (TSE:KSI) Reaches New 12-Month High – Still a Buy?

kneat.com, inc. (TSE:KSI)’s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as C$6.87 and last traded at C$6.84, with a volume of 166540 shares changing hands. The stock had previously closed at C$6.57.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Cibc World Mkts upgraded kneat.com to a “strong-buy” rating in a research note on Tuesday, October 29th. CIBC set a C$6.00 price objective on kneat.com and gave the company an “outperform” rating in a research note on Tuesday, October 29th.

kneat.com Stock Performance

The company has a 50-day moving average price of C$6.06 and a two-hundred day moving average price of C$5.22. The stock has a market capitalization of C$588.24 million, a P/E ratio of -42.75, a PEG ratio of 597.67 and a beta of 1.08. The company has a quick ratio of 1.50, a current ratio of 1.47 and a debt-to-equity ratio of 95.14.

kneat.com (TSE:KSI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported C$0.01 earnings per share for the quarter, beating the consensus estimate of C($0.05) by C$0.06. kneat.com had a negative return on equity of 51.13% and a negative net margin of 31.19%. During the same quarter in the previous year, the firm earned ($0.05) EPS. Equities analysts expect that kneat.com, inc. will post -0.12 earnings per share for the current year.

About kneat.com

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.